Status:
COMPLETED
Effects of Nateglinide vs Acarbose on Postprandial Glucose Fluctuation, Dyslipidemia, and Inflammatory Factors
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study was conducted to demonstrate superiority of nateglinide in postprandial glucose fluctuation, dyslipidemia, and inflammatory status improvement.
Eligibility Criteria
Inclusion
- Newly diagnosed type 2 diabetes mellitus patients
- HbA1c \> 6.5 and \< 9.0%
- Fasting fingertip capillary blood glucose (FCBG) \< 9 mmol/L after 2 weeks diet control
Exclusion
- History of acute metabolic complications in the past 3 months or of severe diabetic complications or severe infections or active substance abuse
- Liver disease
- Patients under oral hypoglycemic drugs and/or insulin treatment, or corticosteroid treatment within past 4 weeks
- Other protocol-defined inclusion/exclusion criteria applied to the study.
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2010
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00928889
Start Date
July 1 2009
End Date
June 1 2010
Last Update
May 10 2012
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
People's Liberation Army. The Military General Hospital of BeiJing
Beijing, China, 100020
2
Peiking University First Hospital
Beijing, China, 100034
3
Chinese PLA General Hospital
Beijing, China, 100853
4
The First Affiliated Hospital, Zhongshan (Sun Yat-sen) University
Guangzhou, China, 510080